Development of a Sensitive and Specific RPA-CRISPR/Cas12a Assay for Intrahepatic Quantification of HBV cccDNA
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27010551 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Pattida Kongsomboonchoke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Hauptthemen laut MEDLINE: Hepatitis B virus, DNA, Circular, CRISPR-Cas Systems, DNA, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Second Century Fund (C2F), Center of Excellence in Hepatitis and Liver Cancer.
Abstract (Originalsprache)
Hepatitis B virus (HBV) persists in infected hepatocytes through covalently closed circular DNA (cccDNA), a stable episomal form that serves as the transcriptional template for viral replication. Accurate and sensitive quantification of intrahepatic cccDNA is crucial for evaluating antiviral therapies, particularly those targeting a functional cure. Here, we report the development of a novel, cccDNA-specific detection system combining recombinase polymerase amplification (RPA) with CRISPR/Cas12a-based fluorescence detection. We designed and validated CRISPR RNAs (crRNAs) targeting HBV cccDNA-specific regions conserved across genotypes A–D. Reaction conditions for both RPA and Cas12a detection were optimized to enhance sensitivity, specificity, and accuracy. The system reliably detected as few as 10 copies of cccDNA-containing plasmid per reaction and showed no cross-reactivity with non-cccDNA forms in serum or plasma, indicating assay specificity. When applied to liver tissue samples from 10 HBV-infected and 6 non-HBV patients, the RPA-CRISPR/Cas12a assay exhibited a high sensitivity (90%) and a strong correlation with qPCR results (R2 = 0.9155), confirming its accuracy. In the conclusion, the RPA-CRISPR/Cas12a system provides a robust, cost-effective, and scalable platform for sensitive and specific quantification of intrahepatic HBV cccDNA. This method holds promises for research and high-throughput therapeutic screening applications targeting cccDNA clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
- Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
- Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
ORCID-Profile: Pattida Kongsomboonchoke, Chaiyaboot Ariyachet, Pisit Tangkijvanich
Förderung
- Second Century Fund (C2F)
- Center of Excellence in Hepatitis and Liver Cancer
Zitieren
APA
Kongsomboonchoke, P., Ariyachet, C., Kaewsapsak, P., Sirichindakul, P., & Tangkijvanich, P. (2026). Development of a Sensitive and Specific RPA-CRISPR/Cas12a Assay for Intrahepatic Quantification of HBV cccDNA. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010551
Vancouver
Kongsomboonchoke P, Ariyachet C, Kaewsapsak P, Sirichindakul P, Tangkijvanich P. Development of a Sensitive and Specific RPA-CRISPR/Cas12a Assay for Intrahepatic Quantification of HBV cccDNA. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27010551
BibTeX
@article{Kongsomboonchoke2026,
author = {Kongsomboonchoke, Pattida and Ariyachet, Chaiyaboot and Kaewsapsak, Pornchai and Sirichindakul, Pongserath and Tangkijvanich, Pisit},
title = {Development of a Sensitive and Specific RPA-CRISPR/Cas12a Assay for Intrahepatic Quantification of HBV cccDNA},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27010551}
}
EUVIMED